Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hannah L. Turner is active.

Publication


Featured researches published by Hannah L. Turner.


Cell | 2016

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection

Andrew I. Flyak; Xiaoli Shen; Charles D. Murin; Hannah L. Turner; Joshua A. David; Marnie L. Fusco; Rebecca Lampley; Nurgun Kose; Philipp A. Ilinykh; Natalia Kuzmina; Andre Branchizio; Hannah King; Leland Brown; Christopher Bryan; Edgar Davidson; Benjamin J. Doranz; James C. Slaughter; Gopal Sapparapu; Curtis Klages; Thomas G. Ksiazek; Erica Ollmann Saphire; Andrew B. Ward; Alexander Bukreyev; James E. Crowe

Recent studies have suggested that antibody-mediated protection against the Ebolaviruses may be achievable, but little is known about whether or not antibodies can confer cross-reactive protection against viruses belonging to diverse Ebolavirus species, such as Ebola virus (EBOV), Sudan virus (SUDV), and Bundibugyo virus (BDBV). We isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycoprotein (GP) using peripheral blood B cells from survivors of the 2007 BDBV outbreak in Uganda. We determined that a large proportion of mAbs with potent neutralizing activity against BDBV bind to the glycan cap and recognize diverse epitopes within this major antigenic site. We identified several glycan cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb that completely protected guinea pigs from the lethal challenge with heterologous EBOV. Our results provide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus infections.


Science | 2016

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak

Zachary A. Bornholdt; Hannah L. Turner; Charles D. Murin; Wen Li; Devin Sok; Colby A. Souders; Ashley E. Piper; Arthur J. Goff; Joshua D. Shamblin; Suzanne E. Wollen; Thomas R. Sprague; Marnie L. Fusco; Kathleen B.J. Pommert; Lisa A. Cavacini; Heidi L. Smith; Mark S. Klempner; Keith A. Reimann; Eric Krauland; Tillman U. Gerngross; Karl Dane Wittrup; Erica Ollmann Saphire; Dennis R. Burton; Pamela J. Glass; Andrew B. Ward; Laura M. Walker

Profiling the antibody response to Ebola The recent Ebola virus outbreak in West Africa illustrates the need not only for a vaccine but for potential therapies, too. One promising therapy is monoclonal antibodies that target Ebolas membrane-anchored glycoprotein (GP). Bornholdt et al. isolated and characterized 349 antibodies from a survivor of the 2014 outbreak. A large fraction showed some neutralizing activity and several were quite potent. Structural analysis revealed an important site of vulnerability on the membrane stalk region of GP. Antibodies targeting this area were therapeutically effective in Ebola virus–infected mice. Science, this issue p. 1078 Antibodies from a survivor of the 2014 outbreak bind to the membrane proximal region of the Ebola virus glycoprotein. Antibodies targeting the Ebola virus surface glycoprotein (EBOV GP) are implicated in protection against lethal disease, but the characteristics of the human antibody response to EBOV GP remain poorly understood. We isolated and characterized 349 GP-specific monoclonal antibodies (mAbs) from the peripheral B cells of a convalescent donor who survived the 2014 EBOV Zaire outbreak. Remarkably, 77% of the mAbs neutralize live EBOV, and several mAbs exhibit unprecedented potency. Structures of selected mAbs in complex with GP reveal a site of vulnerability located in the GP stalk region proximal to the viral membrane. Neutralizing antibodies targeting this site show potent therapeutic efficacy against lethal EBOV challenge in mice. The results provide a framework for the design of new EBOV vaccine candidates and immunotherapies.


Nature | 2016

Pre-fusion structure of a human coronavirus spike protein

Robert N. Kirchdoerfer; Christopher A. Cottrell; Nianshuang Wang; Jesper Pallesen; Hadi M. Yassine; Hannah L. Turner; Kizzmekia S. Corbett; Barney S. Graham; Jason S. McLellan; Andrew B. Ward

HKU1 is a human betacoronavirus that causes mild yet prevalent respiratory disease, and is related to the zoonotic SARS and MERS betacoronaviruses, which have high fatality rates and pandemic potential. Cell tropism and host range is determined in part by the coronavirus spike (S) protein, which binds cellular receptors and mediates membrane fusion. As the largest known class I fusion protein, its size and extensive glycosylation have hindered structural studies of the full ectodomain, thus preventing a molecular understanding of its function and limiting development of effective interventions. Here we present the 4.0 Å resolution structure of the trimeric HKU1 S protein determined using single-particle cryo-electron microscopy. In the pre-fusion conformation, the receptor-binding subunits, S1, rest above the fusion-mediating subunits, S2, preventing their conformational rearrangement. Surprisingly, the S1 C-terminal domains are interdigitated and form extensive quaternary interactions that occlude surfaces known in other coronaviruses to bind protein receptors. These features, along with the location of the two protease sites known to be important for coronavirus entry, provide a structural basis to support a model of membrane fusion mediated by progressive S protein destabilization through receptor binding and proteolytic cleavage. These studies should also serve as a foundation for the structure-based design of betacoronavirus vaccine immunogens.


Cell | 2017

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses

Anna Z. Wec; Andrew S. Herbert; Charles D. Murin; Elisabeth K. Nyakatura; Dafna M. Abelson; J. Maximilian Fels; Shihua He; Rebekah M. James; Marc Antoine de La Vega; Wenjun Zhu; Russell R. Bakken; Eileen Goodwin; Hannah L. Turner; Rohit K. Jangra; Larry Zeitlin; Xiangguo Qiu; Jonathan R. Lai; Laura M. Walker; Andrew B. Ward; John M. Dye; Kartik Chandran; Zachary A. Bornholdt

Experimental monoclonal antibody (mAb) therapies have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specific recognition of the viral glycoprotein (GP) has limited their use against other divergent ebolaviruses associated with human disease. Here, we mined the human immune response to natural EBOV infection and identified mAbs with exceptionally potent pan-ebolavirus neutralizing activity and protective efficacy against three virulent ebolaviruses. These mAbs recognize an inter-protomer epitope in the GP fusion loop, a critical and conserved element of the viral membrane fusion machinery, and neutralize viral entry by targeting a proteolytically primed, fusion-competent GP intermediate (GPCL) generated in host cell endosomes. Only a few somatic hypermutations are required for broad antiviral activity, and germline-approximating variants display enhanced GPCL recognition, suggesting that such antibodies could be elicited more efficiently with suitably optimized GP immunogens. Our findings inform the development of both broadly effective immunotherapeutics and vaccines against filoviruses.


Cell Reports | 2016

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site

Katie A. Howell; Xiangguo Qiu; Jennifer M. Brannan; Christopher Bryan; Edgar Davidson; Frederick W. Holtsberg; Anna Z. Wec; Sergey Shulenin; Julia E. Biggins; Robin Douglas; Sven Enterlein; Hannah L. Turner; Jesper Pallesen; Charles D. Murin; Shihua He; Andrea Kroeker; Hong Vu; Andrew S. Herbert; Marnie L. Fusco; Elisabeth K. Nyakatura; Jonathan R. Lai; Zhen Yong Keck; Steven K. H. Foung; Erica Ollmann Saphire; Larry Zeitlin; Andrew B. Ward; Kartik Chandran; Benjamin J. Doranz; Gary P. Kobinger; John M. Dye

Summary Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection against EBOV and SUDV in mice and guinea pigs. The antibody cocktail ZMapp™ is remarkably effective against EBOV (Zaire) but does not cross-neutralize other ebolaviruses. By replacing one of the ZMapp™ components with FVM04, we retained the anti-EBOV efficacy while extending the breadth of protection to SUDV, thereby generating a cross-protective antibody cocktail. In addition, we report several mutations at the base of the ebolavirus glycoprotein that enhance the binding of FVM04 and other cross-reactive antibodies. These findings have important implications for pan-ebolavirus vaccine development and defining broadly protective antibody cocktails.


Nature microbiology | 2016

Structures of Ebola virus GP and sGP in complex with therapeutic antibodies

Jesper Pallesen; Charles D. Murin; Natalia de Val; Christopher A. Cottrell; Kathryn M. Hastie; Hannah L. Turner; Marnie L. Fusco; Andrew I. Flyak; Larry Zeitlin; James E. Crowe; Kristian G. Andersen; Erica Ollmann Saphire; Andrew B. Ward

The Ebola virus (EBOV) GP gene encodes two glycoproteins. The major product is a soluble, dimeric glycoprotein (sGP) that is secreted abundantly. Despite the abundance of sGP during infection, little is known regarding its structure or functional role. A minor product, resulting from transcriptional editing, is the transmembrane-anchored, trimeric viral surface glycoprotein (GP). GP mediates attachment to and entry into host cells, and is the intended target of antibody therapeutics. Because large portions of sequence are shared between GP and sGP, it has been hypothesized that sGP may potentially subvert the immune response or may contribute to pathogenicity. In this study, we present cryo-electron microscopy structures of GP and sGP in complex with GP-specific and GP/sGP cross-reactive antibodies undergoing human clinical trials. The structure of the sGP dimer presented here, in complex with both an sGP-specific antibody and a GP/sGP cross-reactive antibody, permits us to unambiguously assign the oligomeric arrangement of sGP and compare its structure and epitope presentation to those of GP. We also provide biophysical evaluation of naturally occurring GP/sGP mutations that fall within the footprints identified by our high-resolution structures. Taken together, our data provide a detailed and more complete picture of the accessible Ebolavirus glycoprotein landscape and a structural basis to evaluate patient and vaccine antibody responses towards differently structured products of the GP gene.


Proceedings of the National Academy of Sciences of the United States of America | 2017

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.

Jesper Pallesen; Nianshuang Wang; Kizzmekia S. Corbett; Daniel Wrapp; Robert N. Kirchdoerfer; Hannah L. Turner; Christopher A. Cottrell; Michelle M. Becker; Lingshu Wang; Wei Shi; Wing-Pui Kong; Erica L. Andres; Arminja N. Kettenbach; Mark R. Denison; James D. Chappell; Barney S. Graham; Andrew B. Ward; Jason S. McLellan

Significance Coronaviruses such as Middle East respiratory syndrome coronavirus (MERS-CoV) cause severe respiratory distress with high fatality rates. The spike (S) glycoprotein is a determinant of host range and is the target of neutralizing antibodies and subunit vaccine development. We describe an engineering strategy for stabilization of soluble S proteins in the prefusion conformation, which results in greatly increased expression, conformational homogeneity, and elicitation of potent antibody responses. Cryo-EM structures of the stabilized MERS-CoV S protein in complex with a stem-directed neutralizing antibody provide a molecular basis for host-cell protease requirements and identify a site of immune pressure. We also defined four conformational states of the trimer wherein each receptor-binding domain is either packed together at the membrane-distal apex or rotated into a receptor-accessible conformation. Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus that since its emergence in 2012 has caused outbreaks in human populations with case-fatality rates of ∼36%. As in other coronaviruses, the spike (S) glycoprotein of MERS-CoV mediates receptor recognition and membrane fusion and is the primary target of the humoral immune response during infection. Here we use structure-based design to develop a generalizable strategy for retaining coronavirus S proteins in the antigenically optimal prefusion conformation and demonstrate that our engineered immunogen is able to elicit high neutralizing antibody titers against MERS-CoV. We also determined high-resolution structures of the trimeric MERS-CoV S ectodomain in complex with G4, a stem-directed neutralizing antibody. The structures reveal that G4 recognizes a glycosylated loop that is variable among coronaviruses and they define four conformational states of the trimer wherein each receptor-binding domain is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation. Our studies suggest a potential mechanism for fusion initiation through sequential receptor-binding events and provide a foundation for the structure-based design of coronavirus vaccines.


Nature microbiology | 2018

Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region

Andrew I. Flyak; Natalia Kuzmina; Charles D. Murin; Christopher Bryan; Edgar Davidson; Pavlo Gilchuk; Christopher P. Gulka; Philipp A. Ilinykh; Xiaoli Shen; Kai Huang; Palaniappan Ramanathan; Hannah L. Turner; Marnie L. Fusco; Rebecca Lampley; Nurgun Kose; Hannah King; Gopal Sapparapu; Benjamin J. Doranz; Thomas G. Ksiazek; David W. Wright; Erica Ollmann Saphire; Andrew B. Ward; Alexander Bukreyev; James E. Crowe

Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several strategies have been developed in the past to treat EBOV infection, including the antibody cocktail ZMapp, which has been shown to be effective in nonhuman primate models of infection1 and has been used under compassionate-treatment protocols in humans2. ZMapp is a mixture of three chimerized murine monoclonal antibodies (mAbs)3–6 that target EBOV-specific epitopes on the surface glycoprotein7,8. However, ZMapp mAbs do not neutralize other species from the genus Ebolavirus, such as Bundibugyo virus (BDBV), Reston virus (RESTV) or Sudan virus (SUDV). Here, we describe three naturally occurring human cross-neutralizing mAbs, from BDBV survivors, that target an antigenic site in the canonical heptad repeat 2 (HR2) region near the membrane-proximal external region (MPER) of the glycoprotein. The identification of a conserved neutralizing antigenic site in the glycoprotein suggests that these mAbs could be used to design universal antibody therapeutics against diverse ebolavirus species. Furthermore, we found that immunization with a peptide comprising the HR2–MPER antigenic site elicits neutralizing antibodies in rabbits. Structural features determined by conserved residues in the antigenic site described here could inform an epitope-based vaccine design against infection caused by diverse ebolavirus species.Cross-neutralizing antibodies from human survivors of the West Africa Ebola outbreak target a conserved membrane-proximal region in the virus glycoprotein HR2–MPER, which can be used as an immunogen to elicit neutralizing antibodies in rabbits.


Nature Communications | 2018

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

James J. Steinhardt; Javier Guenaga; Hannah L. Turner; Krisha McKee; Mark K. Louder; Sijy O’Dell; Chi-I Chiang; Lin Lei; Andrey Galkin; Alexander K. Andrianov; Nicole A. Doria-Rose; Robert T. Bailer; Andrew B. Ward; John R. Mascola; Yuxing Li

HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a “single” agent to simultaneously target distinct Env epitopes is desirable to overcome viral diversity. Here, we report the use of tandem single-chain variable fragment (ScFv) domains of two bNAbs, specific for the CD4-binding site and V3 glycan patch, to form anti-HIV-1 bispecific ScFvs (Bi-ScFvs). The optimal Bi-ScFv crosslinks adjacent protomers within one HIV-1 Env spike and has greater neutralization breadth than its parental bNAbs. Furthermore, the combination of this Bi-ScFv with a third bNAb recognizing the Env membrane proximal external region (MPER) results in a trispecific bNAb, which has nearly pan-isolate neutralization breadth and high potency. Thus, multispecific antibodies combining functional moieties of bNAbs could achieve outstanding neutralization capacity with augmented avidity.Broadly neutralizing antibodies targeting HIV Env could potentially be utilized as therapeutics. Here, Steinhardt et al. engineer a trispecific antibody with specificity for the receptor-binding site, a conserved Env glycan patch and the Env membrane proximal region with nearly pan-isolate neutralization breadth and high potency.


The Journal of Infectious Diseases | 2018

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Kristen E. Pascal; Drew Dudgeon; John Trefry; Manu Anantpadma; Yasuteru Sakurai; Charles D. Murin; Hannah L. Turner; Jeanette L. Fairhurst; Marcela Torres; Ashique Rafique; Ying Yan; Ashok Badithe; Kevin Yu; Terra Potocky; Sandra L. Bixler; Taylor B. Chance; William D. Pratt; Franco Rossi; Joshua D. Shamblin; Suzanne E. Wollen; Justine M. Zelko; Ricardo Carrion; Gabriella Worwa; Hilary Staples; Darya Burakov; Robert Babb; Gang Chen; Joel H. Martin; Tammy T. Huang; Karl Erlandson

Abstract Background For most classes of drugs, rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety, and pharmacokinetic profiles. Fully human monoclonal antibodies (mAbs) provide an attractive method to overcome many of these hurdles to rapidly produce therapeutics for emerging diseases. Methods In this study, we deployed a platform to generate, test, and develop fully human antibodies to Zaire ebolavirus. We obtained specific anti-Ebola virus (EBOV) antibodies by immunizing VelocImmune mice that use human immunoglobulin variable regions in their humoral responses. Results Of the antibody clones isolated, 3 were selected as best at neutralizing EBOV and triggering FcγRIIIa. Binding studies and negative-stain electron microscopy revealed that the 3 selected antibodies bind to non-overlapping epitopes, including a potentially new protective epitope not targeted by other antibody-based treatments. When combined, a single dose of a cocktail of the 3 antibodies protected nonhuman primates (NHPs) from EBOV disease even after disease symptoms were apparent. Conclusions This antibody cocktail provides complementary mechanisms of actions, incorporates novel specificities, and demonstrates high-level postexposure protection from lethal EBOV disease in NHPs. It is now undergoing testing in normal healthy volunteers in preparation for potential use in future Ebola epidemics.

Collaboration


Dive into the Hannah L. Turner's collaboration.

Top Co-Authors

Avatar

Andrew B. Ward

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Jesper Pallesen

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar

Charles D. Murin

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marnie L. Fusco

Scripps Research Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James E. Crowe

Vanderbilt University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Shihua He

Public Health Agency of Canada

View shared research outputs
Researchain Logo
Decentralizing Knowledge